Skip to main content

Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer

Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
The NSCLC drug market is driven by advancements in targeted therapies, such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), which offer improved efficacy and tolerability compared to traditional chemotherapy.

According to the latest research study, the demand of global Non-Small-Cell Lung Cancer Drug Market size & share was valued at approximately USD 31,614.8 Million in 2023 and is expected to reach USD 34,175.6 Million in 2024 and is expected to reach a value of around USD 68,888.6 Million by 2033, at a compound annual growth rate (CAGR) of about 8.1% during the forecast period 2024 to 2033.

MAIA Biotechnology, Inc. (NYSE American: MAIA), a trailblazer in clinical-stage biopharmaceuticals, revealed impressive efficacy data from the Phase 2 THIO-101 clinical trial of THIO in sequence with the immune checkpoint inhibitor cemiplimab (Libtayo®) for treating advanced non-small cell lung cancer (NSCLC). The latest findings, which were showcased during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, demonstrate significant superiority over standard-of-care therapies, particularly in patients who have undergone multiple prior treatments.

The updated trial results revealed a notable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% with the THIO + cemiplimab combination in third-line treatments—figures that starkly outpace the standard-of-care ORR of 6–10% and DCR of 25–35% typically observed with chemotherapy alone. These data underscore the potential of THIO as a formidable alternative in the NSCLC therapeutic landscape.

Transformative Results in Third-Line Treatment

The THIO-101 trial, which focuses on the safety, tolerability, and efficacy of THIO as both an anticancer agent and an immune system primer, reported encouraging survival metrics. Notably, 65% of participants surpassed the 5.8-month overall survival (OS) benchmark, with a median follow-up time of 9.1 months. Additionally, the optimized dose of 180mg of THIO achieved a median progression-free survival (PFS) of 5.5 months and an OS rate of 78% at six months.

MAIA's Chairman and CEO, Dr. Vlad Vitoc, expressed enthusiasm about the results: "The exceptional measures of efficacy in our trial to date have exceeded our own expectations and significantly outperformed standard of care treatments. The data presented at ASCO advances THIO’s clinical profile as a strong, safe, and highly effective alternative for patients who have progressed following chemotherapy and other available treatments."

THIO: A Novel Approach to Cancer Treatment

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is an investigational telomere-targeting agent designed to disrupt the survival mechanisms of cancer cells. By inducing telomerase-dependent DNA damage and activating both innate and adaptive immune responses, THIO shows promise in overcoming the resistance often encountered with current therapies.

The THIO-101 Phase 2 trial represents a pioneering effort to assess the efficacy of THIO when used in conjunction with PD-(L)1 inhibitors like cemiplimab. This approach not only aims to enhance the immune response but also to establish a durable clinical remission in patients with advanced NSCLC who have exhausted other treatment options.

Looking Ahead

With full enrollment completed ahead of schedule, MAIA anticipates further compelling data from the THIO-101 trial in the latter half of this year. This could potentially position THIO as a first-in-class telomere targeting agent in the field of cancer drug discovery and treatment.

MAIA's ongoing commitment to advancing cancer treatment underscores its role as a leader in targeted therapy and immuno-oncology, aiming to significantly improve and extend the lives of those battling cancer. For more information, including access to the poster and updated company presentations, visit [MAIA Biotechnology’s website]

For additional details on the THIO-101 clinical trial, visit [] with identifier NCT05208944.

Other biotech companies to keep on top of radar include Vertex Pharmaceuticals (NASDAQ: VRTX), United Therapeutics (NASDAQ: UTHR), Corcept Therapeutics (NASDAQ: CORT), Neurocrine Biosciences (NASDAQ: NBIX), Halozyme Therapeutics (NASDAQ: HALO).

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of MAIA or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated five hundred dollars by a 3rd party Momentum Media LLC  for content distribution services on MAIA for June 6th, 2025. We own zero shares of MAIA. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person’s use of or access to this content.


Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.